Acutus Medical develops next-generation electrophysiology technology, centered on its AcQMap cardiac imaging and mapping system. AcQMap integrates precision ultrasound atrial anatomy reconstruction with high-definition non-contact charge density mapping and also provides contact mapping capabilities in Europe. The system's increased clarity of arrhythmia pattern mapping supports the development of patient-specific ablation strategies. In June 2019 the company raised $170M — a $100M Series D equity round and a $70M credit facility — to accelerate commercialization and global business development. Proceeds are earmarked to increase market availability of FDA- and CE-marked AcQMap products and a suite of FDA-cleared, EP-designed vascular access products including AcQCross QX, AcQGuide Flex and AcQGuide Mini. Founded in 2011 by Vince Burgess and based in Carlsbad, California, Acutus positions itself to expand adoption of its electrophysiology solutions worldwide. Acutus Medical develops an intracardiac mapping system that provides dynamic arrhythmia visualization to help electrophysiologists view the heart's true activation pattern. The system is used to treat patients with complex atrial arrhythmias. The company is Carlsbad-based. According to a regulatory filing, Acutus has raised $22.8M as part of an ongoing $25M fundraising effort. The recent investment was structured as debt plus warrants from eight investors and has not yet been announced by the company. Acutus has previously raised funding from Deerfield Management Company, Xeraya Capital, Advent Life Sciences, OrbiMed and GE Ventures, though it is unclear which of those investors participated in this latest filing. Acutus Medical commercializes the AcQMap High Resolution Imaging and Mapping System, which creates three-dimensional, high-definition maps of heart chambers and electrical activity in real time to help electrophysiologists diagnose and treat complex arrhythmias. The system is designed to identify arrhythmia mechanisms, guide catheter ablation therapy, and provide immediate feedback by rendering a new complete map on the next heartbeat to confirm therapy effectiveness. The company is pursuing CE mark approval in Europe for the full AcQMap product suite and is preparing for commercialization in the U.S. and Europe. Proceeds from the recent financing will fund continued product development across the AcQMap suite, expansion of clinical programs worldwide, and building U.S. and European sales forces. Acutus is a privately held heart rhythm technology company based in Carlsbad, California. The company describes itself as moving from an early-stage startup toward commercial launch as it completes regulatory and clinical milestones. Acutus Medical is a San Diego-based medical device company that develops the AcQMap System, a minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping system to identify sources that cause or sustain complex cardiac arrhythmias, including atrial fibrillation. The company completed an additional $26.2M financing to support its operations. Management said the funds will be used to expand the product portfolio and to continue to innovate and validate the AcQMap System. Acutus is broadening its offerings to include diagnostic catheters, therapeutic catheters and additional therapeutic products. The company will also collaborate with Boise State University to develop an innovative therapeutic technology. Randy Werneth serves as President and CEO. Acutus Medical develops a minimally invasive cardiac catheter and a real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping system intended to identify the origin of irregular heartbeats and improve treatment of atrial fibrillation. The company plans to use recent funding to support product development, clinical trials, regulatory approvals and early commercialization. Acutus was established in 2011 and is based in San Diego, CA. It is led by CEO Randy Werneth and had a team of 25 employees at the time of the report. The company’s core offering emphasizes mapping and dipole density imaging to allow more accurate identification and treatment of arrhythmia sources.

Total raised

$326M

Funding rounds

8

Latest round

Series D

Latest activity

Jun 2019